Our major goal is to study the basis of ligand recognition by GPCRs and determine how orthosteric and allosteric ligands stabilize specific receptor conformations. Together with Project 1 and 3 we will attempt to understand how ligands discriminate not only between different receptor types but to determine how they discriminate between active and inactive conformations. These endeavors will take advantage of the structural data, biophysical and pharmacological analyses to both identify novel compounds that may help to discriminate receptor isoforms. We will take into consideration divergent regions that are not involved in orthosteric, hormone-binding interactions, including the extracellular and intracellular faces ofthe receptor. We will also target regions within the TM domains but outside the orthosteric site, such as the crevice identified in the p-opiate receptor (pOR) crystal structure, between the pOR protomers of the crystallized dimer. Thus, by utilizing regions outside the orthosteric site we may engineer more selectivity into ligands that could potentially be translated to novel therapeutics. We will study how agents (small molecules, peptides and proteins) bind to- and stabilize active and inactive conformations. We will work concurrently with Projects 1 (design) and 3 (structure) to study how ligands structures generated from virtual screening around active and inactive conformations participate may stabilize, or perhaps disrupt these states. We are particularly interested in agents which display cooperative, or allosteric, effects on the hormone binding, or orthosteric site. We will take advantage of our recent crystallographic efforts to understand the basis for G protein activation has offered some insights into how G proteins allosterically alter hormone (agonist) binding.
G protein-coupled receptor (GPCR) signaling pathways remain central conduits in sensing stimuli and in intercellular communication and thus are superb therapeutic targets. The absence of selective ligands that distinguish between receptor isoforms has complicated the study of their biology and also accounted for off target effects as therapeutics. Developing new approaches to introduce more specificity into ligands and therapeutics is paramount for understanding receptor biology and to make safer and more efficacious drugs.
|Korczynska, Magdalena; Clark, Mary J; Valant, Celine et al. (2018) Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor. Proc Natl Acad Sci U S A 115:E2419-E2428|
|Liu, Xiangyu; Ahn, Seungkirl; Kahsai, Alem W et al. (2017) Mechanism of intracellular allosteric ?2AR antagonist revealed by X-ray crystal structure. Nature 548:480-484|
|Fish, Inbar; Stößel, Anne; Eitel, Katrin et al. (2017) Structure-Based Design and Discovery of New M2 Receptor Agonists. J Med Chem 60:9239-9250|
|Stößel, Anne; Brox, Regine; Purkayastha, Nirupam et al. (2017) Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior. Bioorg Med Chem 25:3491-3499|
|Brea, Roberto J; Cole, Christian M; Lyda, Brent R et al. (2017) In Situ Reconstitution of the Adenosine A2A Receptor in Spontaneously Formed Synthetic Liposomes. J Am Chem Soc 139:3607-3610|
|Manglik, Aashish; Lin, Henry; Aryal, Dipendra K et al. (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185-190|
|DeVree, Brian T; Mahoney, Jacob P; Vélez-Ruiz, Gisselle A et al. (2016) Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535:182-6|
|Thal, David M; Sun, Bingfa; Feng, Dan et al. (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531:335-40|
|Mahoney, Jacob P; Sunahara, Roger K (2016) Mechanistic insights into GPCR-G protein interactions. Curr Opin Struct Biol 41:247-254|
|Kruse, Andrew C; Hu, Jianxin; Kobilka, Brian K et al. (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24-30|
Showing the most recent 10 out of 15 publications